Granules India arm gets USFDA nod for narcolepsy treatment drug
Granules India's subsidiary has received approval from the US health regulator for Methylphenidate Hydrochloride extended-release tablets used in the27-11-2018
27-11-2018
Received Approval For ANDA Filed By Granules Pharmaceuticals, Inc.
Received Approval for ANDA filed by Granules Pharmaceuticals, Inc.27-11-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Investor Meeting26-11-2018
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of the Investor Meeting.14-11-2018
Announcement under Regulation 30 (LODR)-Allotment
Allotment of 75,000 equity shares under ESOS 200931-10-2018
Board declares Second Interim Dividend
Granules India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 29, 2018, inter alia, has declared second interim dividend of 25 paise per share of face value of Re. 1/- each representing 25% ofpaid-up capital for the financial year 2018-19.29-10-2018
The Record Date For The Purpose Of Payment Of Second Interim Dividend For The FY 2018-19 Is 10-11-2018
The record date for the purpose of payment of second interim dividend for the FY 2018-19 Is 10-11-201829-10-2018
Financial Results For The Half-Year Ended September 30, 2018.
Financial Results for the half-year ended September 30, 2018.29-10-2018